Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada
Clinical Trials Ontario, Toronto, Ontario, Canada.
BMJ Open. 2022 Feb 21;12(2):e060267. doi: 10.1136/bmjopen-2021-060267.
Building capacity to improve sex/gender knowledge and strengthen patient engagement in clinical trials requires training and support. The overall goal of this 2-year project is to refine, translate and evaluate two web-based open-access patient and investigator decision aids aimed to improve patient engagement partnerships in clinical trials.
Two decision aids were designed in Phase 1 of this programme of research and this protocol describes a subsequent sequential phased approach to refine/translate (Phase 2A) and conduct alpha/usability (Phase 2B) and beta/field (Phase 3) testing. Decision aid development is guided by the International Patient Decision Aid Standards, User-Centred Design, Ottawa Decision-Support Framework and the Ottawa Model of Research Use. We have integrated patient-oriented research methods by engaging patient partners across all phases of our programme of research. Decision aids will first be refined and then translated to French (Phase 2A). Eight iterative cycles of semistructured interviews with 40 participants (20 patient partners and 20 investigators) will be conducted to determine usability (Phase 2B). A pragmatic pre/post pilot study design will then be implemented for field/beta testing using another purposive sample of 80 English-speaking and French-speaking participants (40 patients and 40 investigators). The samples are purposive to ensure an equal representation of English-speaking and French-speaking participants and an equal representation of men and women. Since sex and/or gender differences in utilisation and effectiveness of decision aids have not been previously reported, Phase 3 outcomes will be reported for the total sample and separately for men and women.
Ethics approval has been granted from the University of Toronto (41109, 28 September 2021). Informed consent will be obtained from participants. Dissemination will include co-authored publications, conference presentations, educational national public forums, fact sheets/newsletters, social media sharing and videos/webinars.
为了提高性/别知识并加强患者在临床试验中的参与度,需要培训和支持。该为期两年的项目的总体目标是完善、翻译和评估两个旨在提高临床试验中患者参与伙伴关系的基于网络的开放获取患者和研究人员决策辅助工具。
在本研究计划的第一阶段设计了两个决策辅助工具,本方案描述了随后的顺序分阶段方法,以完善/翻译(第二阶段 A)、进行 alpha/可用性(第二阶段 B)和 beta/现场(第三阶段)测试。决策辅助工具的开发以国际患者决策辅助工具标准、以用户为中心的设计、渥太华决策支持框架和渥太华研究使用模型为指导。我们通过在研究计划的所有阶段都让患者伙伴参与,整合了以患者为中心的研究方法。决策辅助工具将首先进行完善,然后翻译成法语(第二阶段 A)。将进行八轮半结构化访谈,共有 40 名参与者(20 名患者伙伴和 20 名研究人员)参与,以确定可用性(第二阶段 B)。然后将使用另一个有 80 名讲英语和法语的参与者(40 名患者和 40 名研究人员)的实用预/后试点研究设计来进行现场/β测试。样本是有目的选择的,以确保讲英语和法语的参与者以及男女代表的平等。由于之前没有报告过决策辅助工具的利用和效果方面的性别差异,因此第三阶段的结果将报告为总样本的结果,并分别报告为男性和女性的结果。
已获得多伦多大学的伦理批准(41109,2021 年 9 月 28 日)。将从参与者处获得知情同意。传播将包括共同撰写的出版物、会议演讲、国家公共教育论坛、情况说明书/通讯、社交媒体分享和视频/网络研讨会。